Table 5 |
||
| Relationships between mutations and MSI patterns | ||
| Mutation status | N (%) | p |
| BRAF V600E* | ||
| Positive | 18/20 (90%) | 1.000 |
| Negative | 17/19 (89%) | |
| RET/PTC* | ||
| Positive | 13/16 (81%) | 0.642 |
| Negative | 17/19 (89%) | |
| Transitions (IDH1 + NRAS) | ||
| Positive | 9/11 (82%) | 0.631 |
| Negative | 22/25 (88%) | |
| Point mutations (BRAF + IDH1 + NRAS) | ||
| Positive | 35/41 (85%) | 1.000 |
| Negative | 22/25 (88%) | |
* Analysis performed only in the PTC group.
Negative group comprises only samples without any of the alterations investigated.
Santos et al. BMC Cancer 2013 13:79 doi:10.1186/1471-2407-13-79
